drugset / Trial / NCT00902369

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

NCT00902369 ↗

Phase 2 Completed 130 enrolled Asahi Kasei Therapeutics Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study

Timeline

Start
2009-05
Primary completion
2009-10
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AK-106 Small molecule 200 mg —
Subject AK-106 Small molecule 400 mg —
Subject AK-106 Small molecule 600 mg —

Indications